Comparing Avonex vs Vumerity
| Avonex (interferon beta-1a) | Vumerity (diroximel fumarate) |
|
|---|
| Avonex (interferon beta-1a) | Vumerity (diroximel fumarate) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Avonex is a type of interferon beta-1a that may be used to treat adults with multiple sclerosis (MS). It is administered intramuscularly once weekly into the upper thigh. Headache, flu-like... View more |
Prescription only
Vumerity (generic name: diroximel fumarate) is an oral prescription medicine indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults. It is given as a twice-daily medicine... View more |
||||||||
| More about Avonex (interferon beta-1a) | More about Vumerity (diroximel fumarate) | ||||||||
| Ratings & Reviews | |||||||||
|
Avonex has an average rating of 7.3 out of 10 from a total of 46 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 22% reported a negative effect. |
Vumerity has an average rating of 8.7 out of 10 from a total of 7 ratings on Drugs.com. 86% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
|
View all Avonex side effects |
View all Vumerity side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
|||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Vumerity prices |
||||||||
| Dosage Forms | |||||||||
|
|
||||||||
| Brand Names | |||||||||
| Other interferon beta-1a brands include: Avonex Pen, Avonex Prefilled Syringe, Rebif, Rebif Rebidose |
N/A |
||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
3 hours |
1 hour |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 342 drugs are known to interact with Avonex:
|
A total of 640 drugs are known to interact with Vumerity:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
|
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
May 17, 1996 |
October 29, 2019 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Ocrevus
Ocrevus (ocrelizumab) is used for MS to treat relapsing and primary progressive forms of multiple ...
Tecfidera
Tecfidera (dimethyl fumarate) is used to treat relapsing forms of multiple sclerosis. Learn about ...
Briumvi
Briumvi is used to treat relapsing forms of multiple sclerosis (MS) in adults, including clinically ...
Betaseron
Betaseron is used to treat relapsing multiple sclerosis (MS). Learn about side effects ...
Rebif
Rebif is used to treat relapsing forms of multiple sclerosis (MS) in adults, including clinically ...
Ocrevus Zunovo
Ocrevus Zunovo (ocrelizumab and hyaluronidase) is a treatment for relapsing forms of multiple ...
Extavia
Extavia is used to treat the relapsing forms of multiple sclerosis. Learn about side effects ...
Kesimpta
Kesimpta (ofatumumab) is used to treat relapsing forms of multiple sclerosis. Includes Kesimpta ...
Copaxone
Copaxone is used to treat relapsing forms of multiple sclerosis (MS) in adults (including ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.